Medicenna's MDNA113 Shows Superior Safety in Preclinical Trials, Clearing Path to IND Submission
Event summary
- Medicenna presented preclinical data at AACR 2026 showing MDNA113's superior tolerability and wider therapeutic window compared to competing anti-PD-1 x IL-2 bispecifics.
- MDNA113 was well tolerated at doses up to 50 mg/kg in non-human primates, while a comparator bispecific exhibited severe toxicity at much lower doses.
- The company plans to submit an Investigational New Drug (IND) application for MDNA113 in the second half of 2026.
- MDNA113 demonstrated selective tumor targeting and conditional activation, addressing key limitations of first-generation PD-1 x IL-2 bispecifics.
The big picture
Medicenna's MDNA113 represents a significant advancement in the development of PD-1 x IL-2 bispecifics, addressing critical safety and efficacy limitations of first-generation molecules. The positive preclinical data positions Medicenna favorably in the competitive oncology space, where PD-1 inhibitors remain the best-selling class of drugs. The company's ability to leverage its proprietary Superkine platforms could further de-risk clinical development and accelerate the path to market.
What we're watching
- Regulatory Milestones
- Whether Medicenna can successfully navigate the IND submission process and initiate clinical trials for MDNA113 as planned in the second half of 2026.
- Competitive Positioning
- How MDNA113's superior tolerability and efficacy profile will position Medicenna against competitors in the PD-1 x IL-2 bispecific space.
- Commercial Potential
- The pace at which Medicenna can advance MDNA113 through clinical development, given the validated commercial potential of PD-1 x IL-2 bispecifics.
Related topics